Dr. Beka Solomon Named to Scientific American’s SciAm 50 Leading Innovators
In the January 2008 issue of Scientific American, Dr. Beka Solomon was recognized as one of the SciAm 50 leading scientific innovators for her demonstration that bacteriophage disaggregate amyloid plaque when administered intranasally to mice genetically engineered to mimic Alzheimer’s disease.
SciAm 50, Scientific American, January 2008
This year’s SciAm 50 awards are replete with instances of new machines or chemicals that come close to the true meaning of innovation as something entirely new.
Israelis join exclusive science club, Jerusalem Post, December 2007
NeuroPhage is advancing a disease-modifying phage-based approach targeted at Alzheimer’s, Parkinson’s and other neurodegenerative diseases. NeuroPhage was founded in 2006 by Professor Beka Solomon, a leading neuroscience researcher from Tel Aviv University and pioneer of immunotherapy for Alzheimer’s, together with a Cambridge-based entrepreneurial team. NeuroPhage has raised a total of $7.2 million in equity financings to date from private investors. NeuroPhage is based in Cambridge, MA.